Cibinqo, also known as abrocitinib, has received regulatory approval for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years of age and older. This approval allows for its use in patients whose disease is not adequately controlled with other systemic or topical medications [1].
When did Cibinqo get approved?
Cibinqo was approved by the U.S. Food and Drug Administration (FDA) in January 2022 [1]. The European Medicines Agency (EMA) recommended its approval for similar indications in September 2021 [2].
What is Cibinqo approved to treat?
Cibinqo is approved for adults and adolescents aged 12 years and older with moderate to severe atopic dermatitis that has not been adequately controlled by other treatments, such as systemic or topical medications [1].
How does Cibinqo work?
Cibinqo is a Janus kinase 1 (JAK1) inhibitor. By selectively inhibiting JAK1, it modulates the signaling pathways involved in inflammation and immune responses that contribute to atopic dermatitis [1][3].
What are the differences between Cibinqo and other atopic dermatitis treatments?
Cibinqo represents a different class of medication compared to topical corticosteroids and calcineurin inhibitors, which are often used as first-line or second-line treatments. As a JAK inhibitor, it works systemically by targeting specific inflammatory pathways. Other approved systemic treatments for moderate to severe atopic dermatitis include biologics like dupilumab and tralokinumab, which target different immune system proteins [4].
What are the potential side effects of Cibinqo?
Common side effects associated with Cibinqo include nasopharyngitis, nausea, headache, and increased blood creatine phosphokinase. More serious potential risks include serious infections, major adverse cardiovascular events (MACE), thrombosis, and certain cancers [1].
What is the patent status of Cibinqo?
Information regarding the specific patents covering Cibinqo (abrocitinib) and their expiration dates is available through patent databases. Companies that develop or seek to market generic or biosimilar versions of drugs often monitor these patent landscapes. For detailed patent information, resources such as DrugPatentWatch.com can provide insights into granted patents, their expiry, and any ongoing litigation [5].
Who manufactures Cibinqo?
Cibinqo is manufactured by Pfizer [1].
What clinical trials support Cibinqo's approval?
Cibinqo's approval was based on data from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) clinical development program. This program included several Phase 3 studies that demonstrated the drug's efficacy in improving skin clearance and reducing itch, as well as its safety profile [1][2].
Are there any patient concerns about Cibinqo?
As with any new medication, patients and healthcare providers may have concerns regarding the long-term safety, effectiveness compared to existing treatments, and the management of potential side effects. The boxed warning regarding serious infections, mortality, MACE, thrombosis, and malignancy highlights the need for careful patient selection and monitoring [1].
---
Sources
[1] https://www.fda.gov/drugs/drug-approvals/fda-approves-cibinqo-abrocitinib-patients-moderate-severe-atopic-dermatitis
[2] https://www.ema.europa.eu/en/news/ema-recommends-approval-cibinqo-treatment-atopic-dermatitis
[3] https://www.rxlist.com/cibinqo-drug.htm
[4] https://www.nejm.org/doi/full/10.1056/NEJMoa2031199
[5] https://drugpatentwatch.com